ONCAlert | 2018 ASCO Annual Meeting

Five-Year OS Data for Dabrafenib/Trametinib Combo in Melanoma

Georgina V. Long, BSc, PhD, MBBS
Published Online: 6:38 PM, Sun June 4, 2017

Georgina V. Long, BSc, PhD, MBBS, professor of medical melanoma oncology, Melanoma Institute Australia, discusses 5-year overall survival data from a phase II trial of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma during the 2017 ASCO Annual Meeting.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.